Pharmaceuticals · NYSE

MRKMerck & Co., Inc.

Last close
$147.76 +0.6%
52-week range
$91.49 to $156.92
Market cap
$364B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$65.0B
+1% vs FY24
Net income
$18.3B
+7% vs FY24
Free cash flow
$12.4B
-32% vs FY24
Net cash
-$34.5B
Cash $14.6B, debt $49.0B

Stock price

+141% since Dec 2016

Valuation vs its own 10 years

Above its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
152x
11.1x781x
98th percentile, above its median of 26.3x
Price / sales
5.4x
3.1x5.9x
92nd percentile, above its median of 4.5x
EV / EBITDA
40.3x
9.3x62.9x
92nd percentile, above its median of 18.4x
Price / free cash flow
24.7x
13.3x40.2x
62nd percentile, above its median of 24.0x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
152x
Earnings yield
0.7%
Price / sales
5.4x
Price / book
8.1x
Price / operating cash flow
19.5x
EV / EBITDA
40.3x
EV / sales
6.1x
Free cash flow yield
4.0%

Profitability

Gross margin
71.8%
Operating margin
n/a
Net margin
3.6%
Return on equity
5.5%
Return on capital
n/a

n/a: Not reported

Growth per year

Revenue, 3 years
+3.1%
Revenue, 5 years
+9.4%
Revenue, 9 years
+5.6%
EPS, 3 years
+8.4%

Balance sheet

Cash and investments
$9.65B
Total debt
$53.8B
Net cash
-$44.1B
Debt / equity
1.20x
Current ratio
1.35x

Shares and dividend

Shares outstanding
2.47B
Share count, 5 years
-1.3%
Beta, 1 year
0.19
Dividend yield
2.3%
Dividend per share, TTM
$3.40
Payout ratio
341%

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $18.1B
RevenueNet income
Gross profitLatest quarter $13.2B
EBITDALatest quarter $6.83B
Margins73 / 28%
GrossOperatingNet
Earnings per shareLatest quarter $2.04
Cash flowLatest quarter $6.56B
OperatingCapexFree
Cash vs debtLatest quarter $9.65B
Cash and investmentsTotal debt
P/E historyNow 152x
P/E, median 26.3x dashed
P/S historyNow 5.4x
P/S, median 4.5x dashed

Where the revenue comes from

US went from 46% to 56% of revenue in 3 years

Share of revenue by region, fiscal 2022 to 2025, as reported in the 10-K.

USEMEALatin AmericaAsia PacificOther CountriesJPCN
FY22
46%24%9%
$59.3B
FY23
47%22%11%
$60.1B
FY24
50%22%9%
$64.2B
FY25
56%22%
$65.0B
Fiscal 2025 by region
RegionRevenueSharevs FY24
US$36.5B56.2%+13%
EMEA$14.6B22.4%+4%
Latin America$3.41B5.2%-1%
Asia Pacific$2.98B4.6%-2%
Other Countries$2.88B4.4%+12%
JP$2.71B4.2%-17%
CN$1.94B3.0%-65%

Pharmaceuticals peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
LLY ELI LILLY & Co $1.36T +46% n/a46.8x15.7x 60th percentile
JNJ Johnson & Johnson $688B +8% n/a43.4x6.9x 90th percentile
MRK Merck & Co., Inc. $364B +5% n/a152x5.4x 98th percentile
PFE Pfizer Inc $165B +1% n/a41.2x2.6x 97th percentile
BMY Bristol Myers Squibb Co $130B +4% n/a14.1x2.6x 13th percentile
TEVA Teva Pharmaceutical Industries Ltd $51.9B -16% 10.2%103x3.7x Not enough history

The company

Sector
Health Care
Industry
Pharmaceuticals
CEO
Kenneth Frazier
Employees
70,000 (as of 2015)
Founded
1891
Headquarters
Rahway, NJ
Fiscal year ends
December
Website
msd.no

What it does

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about MRK.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 3,522 active funds. Crowd level: crowd building, 3 rising quarters.

Open the Smart money tab